Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Identification of intrinsically immunogenic small cell lung carcinoma (SCLC) subpopulations

ABSTRACT: This SuperSeries is composed of the SubSeries listed below.

ORGANISM(S): Mus musculus Homo sapiens

PROVIDER: GSE168295 | GEO | 2021/03/05

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Identification of intrinsically immunogenic small cell lung carcinoma (SCLC) subpopulations

Project description:SCLC is molecularly and immunologically heterogenous. Here, using transcriptional and epigenomic profiling of plastic SCLC states in human and mouse cell lines, and patient samples, we define the phenotype of a SCLC population marked by increased MHC Class I antigen presentation.

2021-03-04 | GSE168195 | GEO

Identification of intrinsically immunogenic small cell lung carcinoma (SCLC) subpopulations [patient]

2021-03-05 | GSE168266 | GEO

Identification of intrinsically immunogenic small cell lung carcinoma (SCLC) subpopulations [Cell line]

2021-03-05 | GSE168294 | GEO

Identification of intrinsically immunogenic small cell lung carcinoma (SCLC) subpopulations

Project description:Identification of intrinsically immunogenic small cell lung carcinoma (SCLC) subpopulations

| PRJNA706756 | ENA

Identification of intrinsically immunogenic small cell lung carcinoma (SCLC) subpopulations

Project description:Identification of intrinsically immunogenic small cell lung carcinoma (SCLC) subpopulations

| PRJNA706431 | ENA

Identification of intrinsically immunogenic small cell lung carcinoma (SCLC) subpopulations [patient]

Project description:Identification of intrinsically immunogenic small cell lung carcinoma (SCLC) subpopulations [patient]

| PRJNA706705 | ENA

Identification of intrinsically immunogenic small cell lung carcinoma (SCLC) subpopulations [Cell line]

Project description:Identification of intrinsically immunogenic small cell lung carcinoma (SCLC) subpopulations [Cell line]

| PRJNA706757 | ENA

BET Inhibitors Target the SCLC-N subtype of Small Cell Lung Cancer by Blocking NEUROD1 Transactivation

Project description:This SuperSeries is composed of the SubSeries listed below.

2022-11-23 | GSE210114 | GEO

Novel Mouse Cell Lines and In Vivo Models for Human High-Grade Neuroendocrine Lung Carcinoma, Small Cell Lung Carcinoma (SCLC), and Large Cell Neuroendocrine Carcinoma (LCNEC).

Project description:There is a clear need to expand the toolkit of adequate mouse models and cell lines available for preclinical studies of high-grade neuroendocrine lung carcinoma (small cell lung carcinoma (SCLC) and large cell neuroendocrine carcinoma (LCNEC)). SCLC and LCNEC are two highly aggressive tumor types with dismal prognoses and few therapeutic options. Currently, there is an extreme paucity of material, particularly in the case of LCNEC. Given the lack of murine cell lines and transplant models of LCNEC, the need is imperative. In this study, we generated and examined new models of LCNEC and SCLC transplantable cell lines derived from our previously developed primary mouse LCNEC and SCLC tumors. RNA-seq analysis demonstrated that our cell lines and syngeneic tumors maintained the transcriptome program from the original transgenic primary tumor and displayed strong similarities to human SCLC or LCNEC. Importantly, the SCLC transplanted cell lines showed the ability to metastasize and mimic this characteristic of the human condition. In summary, we generated mouse cell line tools that allow further basic and translational research as well as preclinical testing of new treatment strategies for SCLC and LCNEC. These tools retain important features of their human counterparts and address the lack of LCNEC disease models.

| S-EPMC10607103 | biostudies-literature

Ferroptosis response segregates small cell lung cancer (SCLC) neuroendocrine subtypes.

Project description:Loss of TP53 and RB1 in treatment-naïve small cell lung cancer (SCLC) suggests selective pressure to inactivate cell death pathways prior to therapy. Yet, which of these pathways remain available in treatment-naïve SCLC is unknown. Here, through systemic analysis of cell death pathway availability in treatment-naïve SCLC, we identify non-neuroendocrine (NE) SCLC to be vulnerable to ferroptosis through subtype-specific lipidome remodeling. While NE SCLC is ferroptosis resistant, it acquires selective addiction to the TRX anti-oxidant pathway. In experimental settings of non-NE/NE intratumoral heterogeneity, non-NE or NE populations are selectively depleted by ferroptosis or TRX pathway inhibition, respectively. Preventing subtype plasticity observed under single pathway targeting, combined treatment kills established non-NE and NE tumors in xenografts, genetically engineered mouse models of SCLC and patient-derived cells, and identifies a patient subset with drastically improved overall survival. These findings reveal cell death pathway mining as a means to identify rational combination therapies for SCLC.

| S-EPMC8024350 | biostudies-literature

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data